Genmab A/S
GMABNASDAQHealthcare● Active
$24.85
$-0.30(-1.19%)
Market Cap$15.3B
P/E Ratio—
52W High$35.43
52W Low$20.225
Genmab A/S（GMAB）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · GMAB · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.72B | $21.53B | $16.47B | $14.51B | $8.42B |
| Cost of Revenue | $0.31B | $0.98B | $0.23B | $0.00B | $0.00B |
| Gross Profit | $3.41B | $20.54B | $16.25B | $14.51B | $8.42B |
| Gross Margin %(computed) | 91.69% | 95.42% | 98.63% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $1.56B | $9.75B | $7.63B | $5.56B | $4.18B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $2.16B | $13.84B | $10.93B | $8.24B | $5.46B |
| Operating Income | $1.25B | $6.70B | $5.32B | $6.27B | $2.95B |
| Operating Margin %(computed) | 33.60% | 31.14% | 32.30% | 43.21% | 35.08% |
| Interest Income | $0.14B | $0.99B | $0.94B | $0.32B | $0.20B |
| Interest Expense | $0.06B | $0.12B | $0.03B | $0.02B | $0.01B |
| Income Before Tax | $1.20B | $9.16B | $5.64B | $6.95B | $3.92B |
| Income Tax Expense | $0.24B | $1.32B | $1.28B | $1.49B | $0.96B |
| Net Income | $0.96B | $7.84B | $4.35B | $5.45B | $2.96B |
| Net Margin %(computed) | 25.89% | 36.44% | 26.42% | 37.59% | 35.13% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.55 | $12.14 | $6.60 | $8.34 | $4.52 |
| Wtd Avg Shares | 0.62B | 0.65B | 0.66B | 0.65B | 0.65B |
| EBITDA | $1.32B | $9.70B | $5.95B | $7.35B | $4.18B |
| EBITDA Margin %(computed) | 35.51% | 45.05% | 36.10% | 50.64% | 49.67% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解Genmab A/S
关于Genmab A/S（GMAB）损益表
Genmab A/S（GMAB）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，GMAB实现营收$3.72B，毛利润$3.41B（毛利率91.69%），净利润$0.96B（净利率25.89%）。
常见问题
GMAB · 4 问Genmab A/S（GMAB）2025财年营收为$3.72B，同比down82.7%。
GMAB revenueGMAB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08